Related Experiment Videos
Cytokine mRNA expression during experimental corneal allograft rejection
P F Torres1, A F De Vos, R van der Gaag
1Department of Ophthalmology, Hospital Geral de Santo Antonio, Porto, Portugal.
Experimental Eye Research
|October 1, 1996
Summary
Corneal allograft rejection involves specific cytokine mRNA changes, with elevated interleukin-6 and tumor necrosis factor-alpha in allografts post-rejection. Autografts show transient cytokine expression, highlighting molecular differences in graft survival.
Area of Science:
- Immunology
- Ophthalmology
- Molecular Biology
Background:
- Allograft rejection is a primary cause of corneal graft failure.
- T lymphocytes and macrophages are implicated in corneal rejection, but molecular mechanisms remain unclear.
Purpose of the Study:
- To analyze cytokine mRNA expression in corneas during experimental corneal transplantation.
- To investigate molecular differences between allografts and autografts in rats.
Main Methods:
- Rats received either corneal allografts (PVG to AO) or autografts (AO).
- Semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was used to analyze mRNA expression of 11 key cytokines.
- Corneal samples were collected at post-operative days 1, 3, 7, 12, and 19.
Main Results:
- Corneal rejection was observed around post-operative day 12, characterized by opacity and neovascularization.
- Allografts showed sustained mRNA levels for IL-1β, IL-6, IL-10, and TNF-α, with increased IL-6 after day 12.
- Autografts exhibited high cytokine mRNA levels initially, decreasing by day 3 or 7, except for IL-1 receptor antagonist. IL-2, IL-4, and IFN-γ mRNA were absent in autografts and present in allografts only after day 12.
Conclusions:
- Distinct cytokine mRNA expression profiles differentiate corneal allograft rejection from autograft acceptance.
- Elevated IL-6 and TNF-α in allografts post-rejection suggest their role in the inflammatory response.
- The study provides insights into the molecular basis of corneal graft fate, aiding future therapeutic strategies.